​

Agios Pharmaceuticals (AGIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AGIO Stock Forecast

Agios Pharmaceuticals (AGIO) stock forecast, based on 28 Wall Street analysts, predicts a 12-month average price target of $36.75, with a high of $56.00 and a low of $25.00. This represents a 33.93% increase from the last price of $27.44.

$20 $28 $36 $44 $52 $60 High: $56 Avg: $36.75 Low: $25 Last Closed Price: $27.44

AGIO Stock Rating

Agios Pharmaceuticals stock's rating consensus is Buy, based on 28 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 21 Buy (75.00%), 7 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 28 0 7 21 Strong Sell Sell Hold Buy Strong Buy

AGIO Price Target Upside V Benchmarks

TypeNameUpside
StockAgios Pharmaceuticals33.93%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts345
Avg Price Target$30.33$36.75$43.60
Last Closing Price$27.44$27.44$27.44
Upside/Downside10.53%33.93%58.89%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25-73--10
Nov, 25233--8
Oct, 25233--8
Sep, 25233--8
Aug, 25333--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 24, 2025Truist Financial$32.00$25.2426.78%16.62%
Nov 20, 2025Goldman Sachs$25.00$25.55-2.15%-8.89%
Nov 20, 2025Leerink Partners$34.00$22.3452.19%23.91%
Oct 20, 2025Emily BodnarH.C. Wainwright$56.00$42.3332.29%104.08%
May 02, 2025Greg HarrisonScotiabank$71.00$30.10135.88%158.75%
Oct 31, 2024Danielle BrillRaymond James$51.00$44.4314.79%85.86%
Sep 27, 2024Andrew BerensLeerink Partners$56.00$45.6122.78%104.08%
Sep 10, 2024Chris RaymondRaymond James$56.00$44.0527.13%104.08%
Jun 17, 2024Chris RaymondRaymond James$55.00$43.4226.67%100.44%
Jun 03, 2024Gregory RenzaRBC Capital$53.00$44.2619.75%93.15%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 26, 2025CitigroupBuyinitialise
Oct 20, 2025H.C. WainwrightBuyBuyhold
Oct 31, 2024Raymond JamesOutperformOutperformhold
Oct 10, 2024RBC CapitalMarket PerformMarket Performhold
Sep 27, 2024Leerink PartnersMarket Performdowngrade
Sep 10, 2024Piper SandlerOverweightOverweighthold
Jun 03, 2024RBC CapitalOutperformOutperformhold
May 28, 2024Cowen & Co.BuyBuyhold
May 28, 2024Piper SandlerOverweightOverweighthold
Jun 27, 2023RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-15 $-1 $13 $27 $41 $55 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.86$26.55$-1.36$-6.33$11.86----
Avg Forecast$-4.67$25.51$-6.29$-6.26$11.44$-6.14$-5.11$-1.41$1.41
High Forecast$-3.32$50.89$-4.02$-5.91$11.83$-3.30$-3.22$0.04$3.57
Low Forecast$-9.32$18.11$-14.19$-6.60$10.51$-7.05$-7.30$-2.89$0.80
Surprise %4.07%4.08%-78.38%1.12%3.67%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$203.20M-$14.24M$26.82M$36.50M----
Avg Forecast$199.05M$558.82K$13.91M$27.72M$35.15M$95.27M$188.95M$463.37M$715.00M
High Forecast$351.32M$986.30K$27.36M$30.14M$36.47M$112.88M$192.48M$473.16M$1.56B
Low Forecast$154.59M$433.99K$10.06M$25.85M$34.01M$81.62M$185.43M$453.58M$477.00M
Surprise %2.08%-2.36%-3.23%3.83%----

Net Income Forecast

$-5B $6B $17B $28B $39B $50B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-335.22M$1.60B$-74.56M$-352.09M$673.73M----
Avg Forecast$-341.28M$37.63B$-299.44M$-352.09M$621.74M$-366.33M$-324.03M$-114.12M$78.52M
High Forecast$-273.02M$45.23B$-239.56M$-281.67M$658.31M$-183.74M$-179.12M$2.43M$198.66M
Low Forecast$-409.53M$30.03B$-359.33M$-422.51M$585.16M$-392.58M$-406.05M$-160.64M$44.54M
Surprise %-1.78%-95.74%-75.10%-8.36%----

AGIO Forecast FAQ

Is Agios Pharmaceuticals stock a buy?

Agios Pharmaceuticals stock has a consensus rating of Buy, based on 28 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 21 Buy, 7 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Agios Pharmaceuticals is a favorable investment for most analysts.

What is Agios Pharmaceuticals's price target?

Agios Pharmaceuticals's price target, set by 28 Wall Street analysts, averages $36.75 over the next 12 months. The price target range spans from $25 at the low end to $56 at the high end, suggesting a potential 33.93% change from the previous closing price of $27.44.

How does Agios Pharmaceuticals stock forecast compare to its benchmarks?

Agios Pharmaceuticals's stock forecast shows a 33.93% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Agios Pharmaceuticals over the past three months?

  • December 2025: 0% Strong Buy, 70.00% Buy, 30.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 25.00% Strong Buy, 37.50% Buy, 37.50% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 25.00% Strong Buy, 37.50% Buy, 37.50% Hold, 0% Sell, 0% Strong Sell.

What is Agios Pharmaceuticals’s EPS forecast?

Agios Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-6.14, marking a -151.77% decrease from the reported $11.86 in 2024. Estimates for the following years are $-5.11 in 2026, $-1.41 in 2027, and $1.41 in 2028.

What is Agios Pharmaceuticals’s revenue forecast?

Agios Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $95.27M, reflecting a 161.02% increase from the reported $36.5M in 2024. The forecast for 2026 is $188.95M, followed by $463.37M for 2027, and $715M for 2028.

What is Agios Pharmaceuticals’s net income forecast?

Agios Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-366M, representing a -154.37% decrease from the reported $673.72M in 2024. Projections indicate $-324M in 2026, $-114M in 2027, and $78.52M in 2028.